These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28396612)

  • 1. Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    He L; Liu X; Zhao Y; Zhang S; Jiang Y; Wang X; Yang Z
    Dis Markers; 2017; 2017():7075935. PubMed ID: 28396612
    [No Abstract]   [Full Text] [Related]  

  • 2. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
    Sun P; Dong X; Cheng X; Hu Q; Zheng Q
    PLoS One; 2014; 9(7):e102761. PubMed ID: 25058587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy of chronic hepatitis B.
    van Bömmel F; Berg T
    Intervirology; 2014; 57(3-4):171-80. PubMed ID: 25034485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
    J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
    Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G
    Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of antiviral-resistant chronic hepatitis B virus infection].
    Yim HJ
    Korean J Gastroenterol; 2008 Jun; 51(6):346-59. PubMed ID: 18604136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
    Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
    J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
    Toyoda H; Kumada T; Tada T; Sone Y; Fujimori M
    J Vasc Interv Radiol; 2012 Mar; 23(3):317-22.e1. PubMed ID: 22265248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
    Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
    Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
    J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment of chronic hepatitis B.
    Lok AS
    Semin Liver Dis; 2004; 24 Suppl 1():77-82. PubMed ID: 15192805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New approaches in the treatment of hepatitis B].
    Sagir A; Avci A; Erhardt A; Lörke J; Heintges T; Häussinger D
    Dtsch Med Wochenschr; 2004 May; 129(21):1203-8. PubMed ID: 15160325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.